MAX
Company Analysis Galmed Pharmaceuticals Ltd.
1. Summary
Advantages
- Price (0.63 $) is less than fair price (1.6 $)
- Current debt level 0.22% is below 100% and has decreased over 5 years from 0.41%.
Disadvantages
- Dividends (0%) are below the sector average (0.51%).
- The stock's return over the last year (-64.8%) is lower than the sector average (28.89%).
- The company's current efficiency (ROE=-49.77%) is lower than the sector average (ROE=102.4%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Galmed Pharmaceuticals Ltd. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 2.4% | 11.7% | -1.6% |
| 90 days | -25.9% | -1.4% | -4.5% |
| 1 year | -64.8% | 28.9% | 16.5% |
GLMD vs Sector: Galmed Pharmaceuticals Ltd. has significantly underperformed the "Healthcare" sector by -93.69% over the past year.
GLMD vs Market: Galmed Pharmaceuticals Ltd. has significantly underperformed the market by -81.27% over the past year.
Stable price: GLMD is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: GLMD with weekly volatility of -1.25% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (0.63 $) is lower than the fair price (1.6 $).
Price significantly below the fair price: The current price (0.63 $) is 154% lower than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-0.18) is lower than that of the sector as a whole (26.63).
P/E vs Market: The company's P/E (-0.18) is higher than that of the market as a whole (-88.36).
5.3. P/BV
P/BV vs Sector: The company's P/BV (0.18) is lower than that of the sector as a whole (244.09).
P/BV vs Market: The company's P/BV (0.18) is lower than that of the market as a whole (81.84).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (127.74).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (116.29).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (0.24) is higher than that of the sector as a whole (-21.78).
EV/Ebitda vs Market: The company's EV/Ebitda (0.24) is higher than that of the market as a whole (-79.49).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -15.31% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-15.31%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-28.94%).
6.4. ROE
ROE vs Sector: The company's ROE (-49.77%) is lower than that of the sector as a whole (102.4%).
ROE vs Market: The company's ROE (-49.77%) is lower than that of the market as a whole (23.33%).
6.6. ROA
ROA vs Sector: The company's ROA (-42.8%) is lower than that of the sector as a whole (-1.94%).
ROA vs Market: The company's ROA (-42.8%) is lower than that of the market as a whole (4.25%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0.7%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (8.8%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.51%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Based on sources: porti.ru
